Stocks TelegraphStocks Telegraph
Stock Ideas

ST Premium

Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Try Now for Just $1!

PTGX Company Profile and Key Details

NASDAQ : PTGX

Protagonist Therapeutics, Inc.

$46.95
1.92+4.26%
At Close 4:00 PM
58.23
BESG ScoreESG Rating

PTGX Stock Price Chart

Stock Price Today

Protagonist Therapeutics, Inc. (PTGX) stock surged +4.26%, trading at $46.95 on NASDAQ, up from the previous close of $45.03. The stock opened at $45.20, fluctuating between $45.19 and $48.32 in the recent session.

Stock Snapshot

45.03
Prev. Close
45.2
Open
2.88B
Market Cap
61.38M
Number of Shares
45.19
Day Low
48.32
Day High
11.1
P/E Ratio
94.29%
Free Float in %
4.23
EPS (TTM)
5.58
Book Value
-1.17
Cash Flow per Share
1.81M
Volume

Relevant Articles

Stock Price History Chart

DateOpenHighLowCloseVolume
Apr 15, 202545.2048.3244.9746.952.01M
Apr 14, 202543.2245.5142.5345.03960.93K
Apr 11, 202541.1042.6341.1042.621.16M
Apr 10, 202541.4443.0039.9040.891.61M
Apr 09, 202541.0643.9139.6042.611.86M
Apr 08, 202544.1045.8840.8841.691.76M
Apr 07, 202543.4245.3242.4443.211.53M
Apr 04, 202545.0946.4543.9344.441.75M
Apr 03, 202547.0647.2545.7946.501.48M
Apr 02, 202546.6848.9346.3948.201.19M
Apr 01, 202547.9948.6846.5446.881.05M
Mar 31, 202547.9248.8047.0948.361.21M
Mar 28, 202549.4750.4848.8048.88664.5K
Mar 27, 202549.3350.5249.3349.44715.47K
Mar 26, 202551.0951.4049.4049.56881.9K
Mar 25, 202552.6053.5850.7251.05790.4K
Mar 24, 202553.3053.7051.6152.531.52M
Mar 21, 202553.2353.2351.0652.653.7M
Mar 20, 202553.6754.1152.4753.05872.57K
Mar 19, 202554.4554.5452.4354.351.05M

Contact Details

Newark, CA 94560-1160

United States

Website: https://www.protagonist-inc.comContact: 510 474 0170

About Company

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Company Information

Employees126
Beta2.29
Sales or Revenue$60.00M
5Y Sales Change%-0.236%
Fiscal Year EndsDecember
SectorHealthcare
IndustryBiotechnology

Frequently Asked Questions

What is the current Protagonist Therapeutics, Inc. (PTGX) stock price?
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) stock price is $46.95 in the last trading session. During the trading session, PTGX stock reached the peak price of $48.32 while $45.19 was the lowest point it dropped to. The percentage change in PTGX stock occurred in the recent session was 4.26% while the dollar amount for the price change in PTGX stock was $1.92.
PTGX's industry and sector of operation?
The NASDAQ listed PTGX is part of Biotechnology industry that operates in the broader Healthcare sector. Protagonist Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of PTGX?
Ms. Abha Bommireddi
Executive Vice President of Portfolio & Program Management
Dr. Dinesh V. Patel Ph.D.
Chief Executive Officer, Pres, Sec. & Director
Mr. Mohammad Masjedizadeh
Executive Vice President & Chief Technology Officer
Dr. David Y. Liu Ph.D.
Chief R&D Strategy Officer
Mr. Matthew M. Gosling
Executive Vice President & Gen. Counsel
Dr. Richard S. Shames
Clinical Advisor
Dr. Suneel K. Gupta Ph.D.
Chief Devel. Officer
Mr. Asif Ali
Executive Vice President & Chief Financial Officer
Mr. Mohammad Masjedizadeh Ph.D.
Executive Vice President & Chief Technical Officer
Dr. Ashok Bhandari Ph.D.
Executive Vice President & Chief Drug Discovery and Preclinical Devel. Officer
Ms. Carena Spivey
Senior Vice President of HR
Dr. Scott Eric Plevy M.D.
Executive Vice President & Therapeutic Head of Gastroenterology
Dr. Richard S. Shames M.D.
Clinical Advisor
Mr. Carter J. King
Senior Vice President of Bus. Devel.
How PTGX did perform over past 52-week?
PTGX's closing price is 93.85% higher than its 52-week low of $24.22 where as its distance from 52-week high of $60.60 is -22.52%.
How many employees does PTGX have?
Number of PTGX employees currently stands at 126.
Link for PTGX official website?
Official Website of PTGX is: https://www.protagonist-inc.com
How do I contact PTGX?
PTGX could be contacted at phone 510 474 0170 and can also be accessed through its website. PTGX operates from 7707 Gateway Boulevard, Newark, CA 94560-1160, United States.
How many shares of PTGX are traded daily?
PTGX stock volume for the day was 1.81M shares. The average number of PTGX shares traded daily for last 3 months was 1.14M.
What is the market cap of PTGX currently?
The market value of PTGX currently stands at $2.88B with its latest stock price at $46.95 and 61.38M of its shares outstanding.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph